A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor,brivanib, in patients with advanced or metastatic solid tumors by D. Jonker et al.
Annals of Oncology 22: 1413–1419, 2011
doi:10.1093/annonc/mdq599
Published online 3 December 2010
original article
A phase I study to determine the safety,
pharmacokinetics and pharmacodynamics of a dual
VEGFR and FGFR inhibitor, brivanib, in patients with
advanced or metastatic solid tumors
D. J. Jonker1*, L. S. Rosen2, M. B. Sawyer3, F. de Braud4, G. Wilding5, C. J. Sweeney6,
G. C. Jayson7, G. A. McArthur8, G. Rustin9, G. Goss1, J. Kantor10, L. Velasquez10, S. Syed10,
O. Mokliatchouk10, D. M. Feltquate10, G. Kollia10, D. S. A. Nuyten10 & S. Galbraith10
1Division of Medical Oncology, Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, Canada; 2Department of Oncology, Premiere Oncology, Santa Monica,
USA; 3Department of Oncology, Cross Cancer Institute, Edmonton, Canada; 4Division of Clinical Pharmacology and New Drugs, Department of Medicine, European
Institute of Oncology, Milan, Italy; 5Department of Oncology, University of Wisconsin Carbone Cancer Center, Madison; 6Department of Medicine, Dana-Farber Cancer
Institute, Boston, USA; 7Department of Oncology, Christie Hospital, University of Manchester, Manchester, UK; 8Department of Medical Oncology, Peter MacCallum
Cancer Center, East Melbourne, Australia; 9Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood, Middlesex, UK; 10Research and
Development, Bristol-Myers Squibb, Princeton, USA
Received 28 July 2010; revised 27 August 2010; accepted 31 August 2010
Background: This study was designed to determine the safety, pharmacokinetics (PK) and pharmacodynamics
(PD) of brivanib in patients with advanced/metastatic solid tumors.
Patients and methods: Ninety patients enrolled in this two-part, phase I open-label study of oral brivanib alaninate.
The primary objectives of this study were (in part A) dose-limiting toxicity, maximum tolerated dose (MTD) and the
lowest biologically active dose level and (in part B) the optimal dose/dose range. The secondary objectives of this study
were preliminary evidence of antitumor activity, PK and PD.
Results: Across part A (open-label dose escalation and MTD) and part B (open-label dose optimization), 68 patients
received brivanib alaninate. Brivanib demonstrated a manageable toxicity profile at doses of 180–800 mg. Most
toxic effects were mild. Systemic exposure of the active moiety brivanib increased linearly £1000 mg/day. The MTD
was 800 mg/day. Forty-four patients were treated at the MTD: 20 with 800 mg continuously, 11 with 800 mg
intermittently and 13 with 400 mg b.i.d. doses. Partial responses were confirmed in two patients receiving brivanib
‡600 mg. Dynamic contrast-enhanced magnetic resonance imaging demonstrated statistically significant
decreases in parameters reflecting tumor vascularity and permeability after multiple doses in the 800-mg continuous
q.d. and 400-mg b.i.d. dose cohorts.
Conclusion: In patients with advanced/metastatic cancer, brivanib demonstrates promising antiangiogenic and
antitumor activity and manageable toxicity at doses £800 mg orally q.d., the recommended phase II study dose.
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introduction
Angiogenesis plays a key role in growth and metastasis of many
tumors [1] and is generally mediated by a variety of growth
factors, including vascular endothelial growth factor (VEGF)-A
and fibroblast growth factor (FGF)-1 (aFGF) and FGF-2
(bFGF) [1]. Several VEGF-targeted agents, administered either
as single agents or in combination with chemotherapy, provide
survival benefits in patients with advanced-stage malignancies,
including colorectal cancer (CRC), hepatocellular carcinoma
(HCC), renal cell carcinoma (RCC) and non-small-cell lung
cancer [2–6]. However, currently available VEGF-targeted
agents fail to produce enduring clinical responses in most
patients as a result of innate or evasive resistance [7]. Recent
evidence suggests that up-regulation of alternate proangiogenic
signals, such as the FGF signaling pathway, plays a role in the
development of resistance, as in the case of HCC [7–9]. Thus,
dual targeting of FGF and VEGF signaling pathways may
provide another approach to avoiding and overcoming
resistance to VEGF inhibition.
Brivanib alaninate, an ester prodrug of the active moiety
brivanib, is an oral dual inhibitor of FGFR and VEGFR
signaling pathways. Brivanib has shown strong antiangiogenic
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and antitumor effects across a range of tumor cell types,
including colon, breast, liver and lung cancer [10–12].
Here, we report findings from a phase I study designed to
evaluate the safety profile, tolerability, pharmacokinetics (PK)
and pharmacodynamics (PD) of brivanib in patients with
metastatic solid tumors that were refractory to standard
therapies or for whom no standard therapy existed or was
inappropriate.
patients and methods
study design
This was a two-part, phase I open-label study of brivanib alaninate
administered orally (p.o.) to patients with advanced/metastatic solid
tumors. The study was conducted at nine sites: three in the United States,
two in the UK, two in Canada, one in Australia and one in Italy. Part A was
an open-label dose-escalation study in which brivanib alaninate was
administered p.o. on a once-daily schedule at a starting dose of 180 mg. At
least three patients, and a maximum of six, were treated at each dose level.
If a dose-limiting toxicity (DLT; supplemental Appendix A, available at
Annals of Oncology online) was observed in the first three patients in a given
dosing cohort, an additional three patients were enrolled to that dose level
before further dose escalation was considered. Dose escalation proceeded
when at least three patients completed a given cycle (28 days) and
continued until at least one third of patients at a particular dose level had
a DLT. Part B was an open-label study with four cohorts in which patients
were treated with different regimens of brivanib alaninate: (i) 320 mg q.d.
[continuous dosing schedule at the lower end of the biological response
curve based on dynamic contrast-enhanced magnetic resonance imaging
(DCE-MRI) parameters; 320-mg cohort]; (ii) 800 mg q.d. continuous
[continuous dosing at maximum tolerated dose (MTD) defined in part A;
800-mg continuous cohort]; (iii) 800 mg q.d. intermittent [intermittent
dosing (5 days on, 2 days off); 800-mg intermittent cohort] and (iv) 400 mg
twice-daily (b.i.d.) continuous dosing (400-mg b.i.d. cohort). The lower
dose of 320 mg for one expansion cohort was chosen based on preliminary
analysis of DCE-MRI data of the dose-escalation cohorts, showing that the
320 mg dose was the lowest dose level with DCE-MRI changes.
The last visit for each patient was defined as the follow-up visit and
occurred 30 days after the patient was discontinued from the study. All
patients gave informed consent to participate in the study, which was
approved by local ethics committees and conducted in accordance with the
Declaration of Helsinki and locally applicable guidelines on good clinical
practice.
patient eligibility
In part A, patients with a histological or cytological diagnosis of a solid
tumor (nonhematologic malignancy) were enrolled. Patients with
measurable or nonmeasurable disease were eligible. However, patients
planning to undergo DCE-MRI were required to have at least one
lesion ‡2 cm in diameter that was suitable for DCE-MRI imaging. In Part B,
patients with a histological or cytological diagnosis of a tumor type that is
likely to benefit from antiangiogenic therapy—CRC, HCC or clear-cell
RCC—with at least one lesion ‡2 cm in diameter that was suitable for
DCE-MRI imaging were enrolled. Patient inclusion and exclusion criteria
are described in supplemental Appendix B, available at Annals of Oncology
online.
objectives
The primary objectives were to determine the DLTs and MTD of the active
moiety brivanib on a continuous and an intermittent dose schedule in part
A and to determine the lowest biologically active dose for further evaluation
in part B. In part B, primary objectives were to determine the optimal dose
or dose range and schedule for phase II trials from measurement of
brivanib’s effects on DCE-MRI parameters, namely area under the plasma
concentration–time curve for the first 60 s postcontrast agent injection
(IAUC60) and transfer constant (K
trans). Secondary objectives were to (i)
assess any preliminary evidence of antitumor activity observed with
brivanib; (ii) characterize the PK and PD profile of brivanib alaninate and
brivanib following the first oral dose and on days 8 and 26 and (iii) assess
brivanib’s effects on corrected QT (QTc) interval at baseline and on days 1,
8 and 26.
assessments
safety. Safety evaluations were based on medical review of adverse event
(AE) reports and results of vital sign measurements, echocardiograms,
electrocardiograms, physical examinations and clinical laboratory tests. AEs
and other symptoms were graded according to National Cancer Institute–
Common Terminology Criteria for Adverse Events (v.3.0, June, 2003).
pharmacokinetics. Serial plasma PK samples were drawn relative to the time
of dose on days 1, 8 and 26 of cycle 1 only. For those subjects receiving
brivanib alaninate b.i.d., an additional 12-h plasma PK sample was obtained
at days 1, 8 and 26. Brivanib, the active moiety, was measured in plasma by
a validated liquid chromatography/tandem mass spectrometry method as
described in supplemental Appendix C, available at Annals of Oncology
online.
efficacy. Tumor response was assessed at baseline, every 8 weeks and at the
end of treatment using the modified World Health Organization criteria for
tumor response. Tumor response was defined as best overall response with
outcome of complete response (CR) or partial response (PR). Disease
control was defined as a best overall response of CR, PR or stable disease.
Prolonged disease control was defined as best overall response of CR, PR or
stable disease lasting for at least 120 days.
PD biomarkers. DCE-MRI studies to assess changes in tumor perfusion
characteristics were carried out at baseline and on days 2, 8 and 26. Further
details are described in supplemental Appendix D, available at Annals of
Oncology online.
statistical methods
All patients who received study medication were included in the safety
dataset. All patients who received study mediation for at least one treatment
cycle (28 days) were included in the efficacy dataset. In part B, a sample size
of 12 patients in each cohort was calculated to provide 88% power to detect
a 20% difference from baseline at each assessment time with respect to
Ktrans and 98% power to detect a 20% difference from baseline at each
assessment time with respect to AUC60. Therefore, an accrual target of
15 patients per cohort was planned to provide 12 patients to be assessable
for DCE-MRI. Further details on statistical analyses are listed in
supplemental Appendix E, available at Annals of Oncology online.
results
patient disposition and demographics
Ninety patients were enrolled, 68 of whom received at least one
dose of brivanib; the 22 patients who did not receive study
treatment were registered and began study-specific testing, but
subsequently failed screening (Table 1). In part A, 18 patients
were treated with brivanib alaninate in escalating doses; in part
B, 50 patients received brivanib alaninate (see Table 1 for
numbers in each cohort). Baseline demographics are also
shown in Table 1. The majority of patients were white (93%),
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with a median age of 61 years, and 56% were male (Table 1).
Sixty-five percent of patients had CRC and 10% had RCC. All
68 patients had received prior chemotherapy, including prior
systemic anticancer agents, with the majority (96%) receiving
three or more prior chemotherapy regimens. Per the exclusion
criteria, no patient had prior VEGF-targeted therapy.
safety
Brivanib alaninate, at doses of 180, 320, 600 and 800 mg
demonstrated a manageable safety profile in patients with
metastatic or advanced solid tumors across all doses. DLTs were
observed in the 1000-mg dose group; hence, the MTD was
determined to be 800 mg p.o. q.d. At the end of the study,
44 patients had been treated with brivanib alaninate
800 mg/day: 20 patients with 800 mg continuous, 11 patients
with 800 mg intermittent and 13 patients with 400 mg b.i.d.
Safety analysis in the expansion cohort at MTD confirmed
a manageable safety profile.
In patients treated at the MTD (n = 44), the most frequent
serious toxic effects recorded were nausea, pyrexia, aspartate
aminotransferase (AST) or alanine aminotransferase (ALT)
elevations, and thrombocytopenia each in 4.5% of patients.
Most AEs were mild, with no major differences in tolerability
between dose schedules. Frequently occurring treatment-related
toxic effects (>15% with each dosing schedule) at the MTD
(800 mg continuous, 800 mg intermittent and 400 mg b.i.d.)
included nausea, diarrhea, fatigue, dizziness, hypertension,
headache and anorexia. The most frequently occurring
treatment-related toxic effects in brivanib-treated patients are
shown in Tables 2 and 3. No grade five AEs were reported and
no clinically significant QTc prolongation was observed across
the range of brivanib doses investigated. VEGF inhibition class
effects observed with brivanib included hypertension (33.8%),
proteinuria (14.7%), hemorrhage (11.8%), thrombosis-related
events (4.4%) and reversible posterior leukoencephalopathy
(1.5%); there were no reports of bowel perforation or fistulas.
According to prespecified definitions (see supplemental
Appendix A, available at Annals of Oncology online), DLTs were
observed in two of four patients treated in the brivanib
alaninate 1000-mg/day dose cohort. One patient experienced
grade 3 altered mental status considered possibly related to
brivanib, and grade 3 dehydration considered not related to
brivanib, on day 13. The second patient had grade 3 fatigue
related to treatment on day 17. As DLTs occurred in <33% of
patients treated at 800 mg daily, this dose was defined as the
MTD.
Toxic effects led to brivanib discontinuation in 12 (17.6%)
patients; due to study drug toxicity in eight patients (12%) and
non-drug-related AEs in four patients (6%). Reasons for
brivanib discontinuation in these patients included grade 2/3
ALT/AST increased, grade 3 dizziness, grade 3 peripheral
neuropathy, grade 3 reversible posterior leukoencephalopathy
syndrome, grade 2 nausea, grade 1 vomiting, grade 2 chills,
grade 3 fatigue, grade 2 hemorrhagic cystitis, grade 3 renal
failure, grade 2 thrombocytopenia, grade 3 dehydration, grade
3 hypertension and grade 4 elevated bilirubin. Other reasons for
brivanib discontinuation included patient’s request in three
patients (4%), physician’s decision in two patients (3%) and
withdrawn consent in one patient (1%). Two patients
discontinued study therapy due to grade 2/3 elevated liver
function tests and two patients discontinued due to grade 1
vomiting. Of the eight deaths reported during the study, all
were due to disease progression; three patients died within 30
days of receiving the last dose of brivanib alaninate.
pharmacokinetics
Systemic exposure (AUCTAU) of the active moiety of brivanib
alaninate increased in a linear manner with brivanib alaninate
with doses of up to 1000 mg/day (see supplemental Appendix
F, available at Annals of Oncology online). On day 26, the
geometric mean AUCTAU following administration of brivanib
Table 1. Patient disposition in each brivanib dose cohort and baseline
demographics and characteristics
Brivanib dose cohort Patients, n
Part A Part B Total
180 mg 3 0 3
320 mg 3 11 14
600 mg 3 0 3
800 mg continuous 5 15 20
800 mg intermittent 0 11 11
400 mg b.i.d. 0 13 13
1000 mg 4 0 4
Demographic N = 68
Age, years
Median (range) 61 (29–85)
Age category, n (%), years
<65 46 (68)
‡65 22 (32)
Gender, n (%)
Male 38 (56)
Female 30 (44)
Race, n (%)
White 63 (93)
Black 1 (1)
Asian 4 (6)
ECOG, n (%)
0 33 (49)
1 35 (51)
Tumor type, n (%)
Colorectal 44 (65)
Kidney 7 (10)
Hepatocellular carcinoma 2 (3)
Other 15 (22)
Prior therapy, n (%)
Prior surgery 67 (99)
Prior hormonal,
immunologic or biologic
therapy
19 (28)
Prior radiotherapy 23 (34)
Prior chemotherapya 68 (100)
No. of regimens
1 0 (0)
2 3 (4)
‡3 65 (96)
aIncluded prior systemic anticancer agents.
ECOG, Eastern Cooperative Oncology Group.
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alaninate 800 mg continuous was 62 813 ngh/ml [coefficient of
variation (CV), 22%], geometric mean Cmax was 6610 ng/ml
(CV, 39%), median Tmax was 2 h (range 0.77–6.0) and mean
T1/2 was 12.3 h (standard deviation 7.05). At 800 mg
continuous, the median accumulation index of brivanib in
plasma was small (1.62-fold; CV, 53%).
PD activity
Forty-nine patients had double baseline DCE-MRI scans before
treatment. Post-treatment scans were carried out in 52 patients
on day 2 (postdose), 51 patients on day 8 (predose) and 47
patients on day 26 (predose). Reduction in DCE-MRI
parameters was dependent on dose and schedule. A statistically
significant reduction in Ktrans and IAUC60 occurred with
brivanib alaninate for the 800 mg continuous dose starting on
day 2 and for the 800 mg continuous and 400 mg b.i.d. doses
on both day 8 and day 26. However, DCE-MRI parameter
changes were not significant for the 320- and the 800-mg
intermittent dose cohorts (with the exception of day 2;
Table 4). Overall, 14 patients (27% of subjects on day 8 and
30% of subjects on day 26) had an MRI response in IAUC60
(reductions >50%, the IAUC60 repeatability coefficient
Table 2. Selected grade 1/2 treatment-related adverse events commonly reported with vascular endothelial growth factor inhibitors and laboratory test
change by dose (all treated subjects)
180 mg 320 mg 600 mg 800 mg C 800 mg I 1000 mg 400 mg b.i.d.
AEa related to study drug n = 3 n = 14 n = 3 n = 20 n = 11 n = 4 n = 13
Nausea 1 (33) 6 (43) 2 (67) 7 (35) 3 (27) 3 (75) 5 (38.5)
Diarrhea 2 (67) 2 (14) 0 (0) 8 (40) 3 (27) 0 (0) 2 (15)
Fatigue 1 (33) 4 (29) 1 (33) 4 (20) 9 (82) 1 (25) 6 (46)
Dizziness 0 (0) 5 (36) 2 (67) 4 (20) 5 (46) 1 (25) 3 (23)
Hypertension 0 (0) 2 (14) 2 (67) 4 (20) 5 (46) 2 (50) 2 (15)
Vomiting 0 (0) 6 (43) 0 (0) 6 (30) 1 (9) 0 (0) 6 (46)
Constipation 1 (33) 2 (14) 0 (0) 2 (10) 0 (0) 0 (0) 0 (0)
Abdominal pain 0 (0) 1 (7) 0 (0) 1 (5) 1 (9) 0 (0) 0 (0)
Dyspepsia 0 (0) 1 (7) 1 (33) 0 (0) 1 (9) 0 (0) 0 (0)
Stomatitis 0 (0) 0 (0) 0 (0) 1 (5) 1 (9) 1 (25) 0 (0)
Anorexia 2 (67) 4 (29) 3 (100) 6 (30) 3 (27) 3 (75) 7 (54)
Proteinuria 0 (0) 2 (14) 0 (0) 2 (10) 1 (9) 0 (0) 1 (8)
Laboratory testsb n = 3 n = 14 n = 3 n = 20 n = 11 n = 4 n = 10–12
AST increased 0 (0) 0 (0) 1 (33) 2 (10) 0 (0) 2 (50) 1 (8)
ALT increased 0 (0) 1 (7) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Bilirubin increased 0 (0) 0 (0) 0 (0) 1 (5) 0 (0) 0 (0) 0 (0)
Hyponatremia 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
aNational Cancer Institute–Common Terminology Criteria for AEs, v 3.
bGrade increase from baseline.
AE, adverse event; C, continuous; I, intermittent; AST, aspartate aminotransferase; ALT, alanine aminotransferase.
Table 3. Selected grade 3/4 treatment-related adverse events commonly reported with vascular endothelial growth factor inhibitors and laboratory test
change by dose (all treated patients)
180 mg 320 mg 600 mg 800 mg C 800 mg I 1000 mg 400 mg b.i.d.
n = 3 n = 14 n = 3 n = 20 n = 11 n = 4 n = 13
AEa related to study drug
Fatigue 0 (0) 3 (21) 0 (0) 3 (15) 0 (0) 1 (25) 2 (15)
Hypertension 0 (0) 0 (0) 0 (0) 3 (15) 0 (0) 1 (25) 1 (8)
Diarrhea 0 (0) 0 (0) 0 (0) 2 (10) 1 (9) 0 (0) 0 (0)
Dizziness 0 (0) 0 (0) 0 (0) 1 (5) 0 (0) 0 (0) 1 (8)
Nausea 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (8)
Vomiting 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (8)
Laboratory testsb
ALT increased 0 (0) 0 (0) 1 (33) 3 (15) 0 (0) 2 (50) 1 (8)
AST increased 0 (0) 1 (7) 1 (33) 1 (5) 1 (9) 0 (0) 0 (0)
Bilirubin increased 0 (0) 1 (7) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Hyponatremia 1 (33) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (8)
aNational Cancer Institute–Common Terminology Criteria for AEs, v 3.
bGrade increase from baseline.
AE, adverse event; C, continuous; I, intermittent; ALT, alanine aminotransferase; AST, aspartate aminotransferase.
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threshold); 18 (35%) and 14 (30%) subjects had an MRI
response for Ktrans (reductions >52%, the Ktrans repeatability
coefficient threshold) on days 8 and 26, respectively. Figure 1A
and B, respectively, show each patient’s day 26 percent change
from baseline in MRI IAUC60 and K
trans.
antitumor activity: tumor measurements
Preliminary evidence of brivanib antitumor activity was
observed in this study; PRs were confirmed in two patients
treated with brivanib ‡600 mg, one with RCC in the 600-mg
dose cohort and one with ampulla of Vater carcinoma in the
1000-mg dose cohort. Based on the investigator’s assessment in
response-assessable patients, 24 patients (35%) had stable
disease and 32 (47%) had progressive disease (Table 5). A
waterfall plot of the maximum reduction in tumor size in 20
patients (29%) treated with a dose <800 mg and 48 (71%)
treated with a dose of 800 mg or more on study is shown in
Figure 1C.
discussion
In the phase I portion of this study, single-agent brivanib
alaninate had a half-life of 12 h and demonstrated a manageable
toxicity profile at doses of 180–800 mg in patients with
advanced/metastatic cancer. The MTD was determined to be
800 mg/day and was the recommended dose for phase II study
based on the following: PRs were seen at 600 mg/day and
1000 mg/day doses of brivanib; the 1000 mg/day dose was
intolerable and prolonged disease control was also observed at
800 mg/day in these heavily pretreated patients. Significant
changes in DCE-MRI parameters were observed with 800 mg/
day brivanib in the 400-mg p.o. b.i.d. and 800-mg continuous
dosing cohorts. Similar effects were not observed in the 800-mg
intermittent cohort, a finding that lends weight to the
hypothesis that continued inhibition of angiogenic processes is
important for maximum therapeutic effect. Based on observed
toxic effects, splitting the daily dose did not confer a significant
safety advantage over once-daily dosing.
Forty-four patients were treated with an 800 mg/day dose
(MTD) of brivanib alaninate, none of whom reported a DLT.
The most frequently reported drug-related toxic effects were
nausea, diarrhea, fatigue, dizziness, hypertension and anorexia.
Many of these toxic effects are common to the class of VEGFR-
2 inhibitors [2, 4, 13–17]; of note, those reported here with
brivanib at 800 mg/day were mainly mild at grade 1/2. Across
all dose cohorts, the incidence of grade 3/4 hypertension was
Table 4. Percent changes from baseline in IAUC60 and K
trans on days 2, 8 and 26
DCE-MRI parameter Study day Percent change from baseline point estimate (95% CI)
320 mg 800 mg C 800 mg I 400 mg b.i.d.
IAUC60, % (95% CI) 2 24 (–23 to +19) 228a (246 to 28)a 236a (256 to 27) 220a (250 to +28)
8 24 (228 to +19) 237a (251 to 219) 227 (250 to +7) 264a (278 to 242)
26 23 (222 to +21) 247a (260 to 230) 229 (253 to +5) 257a (274 to 230)
Ktrans (95% CI) 2 24 (224 to +21) 231a (249 to 29)a 244a (263 to 216) 231 (258 to +15)
8 26 (225 to +17) 245a (259 to 226) 231 (254 to +5) 264a (278 to 239)
26 26 (226 to +18) 251a (265 to 232) 234 (258 to +2) 259a (276 to 231)
aStatistically significant differences from baseline (P < 0.017).
CI, confidence interval; DCE-MRI, dynamic contrast-enhanced magnetic resonance imaging; C, continuous; I, intermittent; IAUC60, area under the plasma
concentration–time curve for the first 60 s postcontrast agent injection; Ktrans, transfer constant.
Figure 1. (A) Day 26 percent change from baseline in dynamic contrast-
enhanced magnetic resonance imaging (MRI) area under the plasma
concentration–time curve for the first 60 s postcontrast agent injection.
Horizontal lines indicate 95% repeatability coefficients of 250% to 99%.
(B) Ktrans. Horizontal lines indicate 95% repeatability coefficients of
and –52% to 106%. (C) Change in tumor size on study with brivanib
treatment in the total study population (n = 68). Panels A through C are
grouped by patient in ascending order.
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low at 7.4% compared with bevacizumab (5%–18%) but
comparable to that observed with sorafenib and sunitinib
(2%–8%) [4, 18–20]. Likewise, in this small sample size with
brivanib alaninate treatment, there were no reported cases of
grade 3/4 hand–foot syndrome, clinically significant oral toxic
effects or bleeding, events which are commonly (up to 35%)
reported following sunitinib or sorafenib treatment [4, 13, 16,
21–23]. The overall incidence of grade 3/4 AST and ALT
elevation (13.2% and 11.8%, respectively) was higher than
that observed with sunitinib and sorafenib in phase III studies
in HCC and RCC patients; only 2% of patients had grade 3
AST/ALT elevations in a phase III study of sunitinib in RCC
patients [16] and no reported grade 3/4 AST/ALT elevations
have been reported with sorafenib [4, 13]. The reason for this is
unclear, but it has been noted in a separate absorption,
distribution, metabolism and excretion (ADME) study that
brivanib was primarily metabolized by multiple liver
enzymes, including CYP1A2, CYP3A4 and multiple
sulfotransferases [24]. However, similar toxicity has been seen
with the VEGF/PDGF/c-kit inhibitor pazopanib in a phase
III study in which 20% of patients had grade 3/4 AST
elevations [25].
Data from this study confirmed that brivanib has linear PK,
with AUCTAU increasing in approximate proportion to
brivanib alaninate doses. Brivanib PK parameters are
comparable to those observed in an ADME study of brivanib in
patients with advanced/metastatic solid tumors [24].
The DCE-MRI imaging technique was used to assess
brivanib’s effects on tumor permeability and vascularity. This
technique has been used with several VEGF inhibitors, although
the relationship of DCE-MRI changes to clinical benefit still
awaits validation [26–30]. AUC60 and Ktrans parameter values
were very highly correlated within a subject; moreover, due to
the smaller variability and fewer missing values for AUC60,
AUC60 was seen as the primary parameter. Statistically
significant decreases from baseline after multiple doses, in
parameters that reflect tumor vascularity and permeability as
measured by DCE-MRI, were seen at the 800-mg continuous
q.d. dose and 400-mg b.i.d. dose cohorts; a small association
between longer PFS and decrease in DCE-MRI as measured by
AUC60 was observed, but samples were too small to make
formal comparison. No significant decreases from baseline were
seen in the 320- or 800-mg intermittent dose cohort. The
inability of the 800-mg intermittent dose to significantly
reduce DCE-MRI parameters at both day 8 and day 26
might be explained by a rebound in these parameters during
periods when patients are off therapy. Moreover, this
observation indicates that intermittent suppression of
angiogenesis by brivanib may be less effective than continuous
inhibition.
In addition to sample size being too small for a formal
statistical analysis of the association between clinical outcomes
and DCE-MRI parameter changes, other limitations of this
study include that patients were not randomized to the
different dose expansion cohorts and that is was a muticenter
study (although site selection included a qualification process
for DCE-MRI).
Although tumor evaluation was not a primary objective of
this study, preliminary evidence of antitumor activity was
observed, with PRs observed in one patient in the 600-mg dose
cohort and in one patient in the 1000-mg dose cohort.
An ongoing phase II study of brivanib in HCC patients [31]
has demonstrated antitumor activity and manageable
tolerability with brivanib at 800 mg once daily as both first- and
second-line treatment, including those with prior sorafenib
failure. These results, together with its dual inhibition of FGFR
and VEGFR signaling and the potential to overcome resistance
seen with previous studies of VEGFR tyrosine kinase inhibitors,
suggest that brivanib represents an agent of interest in the
management of several malignancies. Determination of the role
of this promising novel agent depends on ongoing trials as
monotherapy and in combination with other treatment
modalities such as transarterial chemoembolization. Molecular
biomarker studies, to be reported separately, will also be
important to identify those patients who may benefit most
from brivanib therapy.
In conclusion, results from this study indicate that brivanib
demonstrates a tolerable safety profile and preliminary
antitumor activity in patients with advanced malignancies.
Given the role of FGF in VEGF resistance, brivanib as a dual
inhibitor of FGFR and VEGFR has the potential to provide
clinical benefits to patients across several tumor types.
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Table 5. Best overall response based on modified World Health Organization assessment and length of time on study
Brivanib dose (mg)
(assessable patientsa)
All doses, n (%) 180 (3) 320 (14) 600 (3) 800 C (20) 800 I (11) 400 b.i.d. (13) 1000 (4)
Response, n
Partial response, n 2 (3) 1b 1c
Stable disease 24 (35) 1 4 1 8 5 4 1
Progressive disease 32 (47) 2 9 1 8 5 6 1
Not assessable 10 (15) 1 4 1 3 1
aAt least one post-treatment scan.
bRenal cell carcinoma.
cAmpulla of Vater.
C, continuous; I, intermittent.
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